icon-folder.gif   Conference Reports for NaTaP  
 
  EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria  april 22-26
Back grey_arrow_rt.gif
 
 
 
Sustained Virologic Response After ACH-3102 and Sofosbuvir Treatment for 8 or 6 Weeks: a Phase 2 "Proxy" Study
 
 
  Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
 
Ed Gane1,2, Christian Schwabe1, Michael Mader3, Vithika Suri2, Mary Donohue3, Mingjun Huang3, James Hui3, Joanna Yang3, Heather Robison3, David Apelian3, Hetal Kocinsky3
Affiliations: 1Auckland Clinical Studies Ltd, Grafton, New Zealand; 2Auckland City Hospital, Auckland, New Zealand; 3Achillion Pharmaceuticals, New Haven, CT, USA

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif